Pharma BD Deal Intelligence
Takeda's flagship Intellikine asset (sapanisertib) never won approval and was divested to Calithera a decade later; the one asset that did reach FDA approval (duvelisib/Copiktra) had already been bought out of Takeda's hands years earlier for a fixed fee.
Full analysis, sources & comparables →Takeda's Millennium oncology arm picks up two novel kinase inhibitors targeting the PI3K/mTOR pathway, adding clinical-stage depth beyond Velcade.
Factual recap: $190 million upfront with up to $120 million in clinical development milestones for Intellikine's PI3K/mTOR kinase inhibitor portfolio; lead…
Sapanisertib (TAK-228) remained in Phase 2 across breast, endometrial, glioblastoma, renal, and thyroid cancers more than a decade after the Takeda…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Takeda America Holdings agreed to acquire Intellikine for $190M upfront plus up to $120M in milestones (~$310M total). Deal added two novel oncology kinase programs to the Millennium oncology pipeline. Closed Q1 2012.
Takeda's flagship Intellikine asset (sapanisertib) never won approval and was divested to Calithera a decade later; the one asset that did reach FDA approval (duvelisib/Copiktra) had already been bought out of Takeda's hands years earlier for a fixed fee.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Intellikine, Inc. (this deal) | 2011 | $310M | 30 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2011 deals · Takeda Pharmaceutical Company Ltd. deals · Hematology deals